Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells
View abstract on PubMed
Summary
This summary is machine-generated.Glypican-1 (GPC1) is essential for tumor growth and metastasis by acting as a coreceptor for growth factors. Targeting GPC1 may offer new therapeutic strategies for cancer and prevent its spread.
Area Of Science
- Oncology
- Molecular Biology
- Biochemistry
Background
- Cancer cells utilize heparin-binding growth factors (HBGFs) for growth, metastasis, and angiogenesis.
- Heparan sulfate proteoglycan glypican-1 (GPC1) functions as a coreceptor for HBGFs, mediating their effects.
Purpose Of The Study
- To investigate the role of both cancer cell- and host-derived GPC1 in tumor growth, metastasis, and angiogenesis.
- To evaluate the therapeutic potential of targeting GPC1 for cancer treatment.
Main Methods
- Downregulation of GPC1 in human pancreatic cancer cells (PANC-1) using antisense approaches.
- Transplantation of GPC1-modified or unmodified cancer cells into athymic mice.
- Analysis of tumor growth, angiogenesis, metastasis, and endothelial cell response in GPC1-deficient mice.
Main Results
- GPC1 downregulation in cancer cells reduced proliferation, anchorage-independent growth, tumor growth, angiogenesis, and metastasis.
- GPC1-deficient mice showed significantly reduced tumor angiogenesis and metastasis after cancer cell implantation.
- Hepatic endothelial cells from GPC1-deficient mice displayed an attenuated mitogenic response to VEGF-A.
Conclusions
- Both cancer cell- and host-derived GPC1 are critical for the full mitogenic, angiogenic, and metastatic potential of cancer cells.
- Targeting GPC1 presents a promising therapeutic strategy for inhibiting cancer progression and metastasis.